Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor-Reference-Cited by-同舟云学术

Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor

Published:2021-05-18 Issue:6 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wang Li¹^ORCID,Zhu Qihui¹,Xiang Kunlun¹,Zhang Yaling¹,Li Baocun¹,Yu Xin¹,Yang Guang¹,Liang Chungen²,Yun Hongying²,Zhang Meifang³,Qin Ning³,Gao Lu¹

Affiliation:

1. Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China

2. Medicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China

3. Lead Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China

Abstract

A high-throughput screen of a Roche internal chemical library based on inhibition of the respiratory syncytial virus (RSV)-induced cytopathic effect (CPE) on HEp-2 cells was performed to identify RSV inhibitors. Over 2,000 hits were identified and confirmed to be efficacious against RSV infection in vitro .

Funder

Roche

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02576-20

Reference53 articles.

1. Respiratory Syncytial Viral Infection in Children with Compromised Immune Function

2. The Burden of Respiratory Syncytial Virus Infection in Young Children

3. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults